Clinical evidence of thiazolidinedione‐induced improvement of pancreatic β‐cell function in patients with type 2 diabetes mellitus
- 1 January 2002
- journal article
- clinical trial
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 4 (1), 56-59
- https://doi.org/10.1046/j.1463-1326.2002.00183.x
Abstract
Background: There is growing evidence in animal and in vitro studies showing that thiazolidinediones (TZDs) improve pancreatic beta cell (β-cell) function. The aim of this study was to evaluate the effect of thiazolidinediones on the β-cell function of patients with Type 2 diabetes mellitus (T2DM) in clinical practice. Patients and Methods: This is an observational, nested case-control study. We identified 28 patients (TZD group), with T2DM, who had had a meal-stimulated C-peptide level documented before the addition of troglitazone to a failing double-therapy regimen with metformin (MET) and sulphonylurea (SU). As a control group (CTRL), we identified 26 patients, with T2DM, who also had had a meal-stimulated C-peptide documented before adding MET to a failing SU monotherapy regimen. We then proceeded to prospectively remeasure their meal-stimulated C-peptide levels and compared the changes over time between the two groups. Results: Both groups were well matched for age, body mass index (BMI), and HgbA1c before and after treatment. The C-peptide in the TZD group increased significantly during therapy (from 3.2 ± 0.5 to 4.2 ± 0.5, p = 0.01), whereas it remained unchanged in the CTRL group (from 4.8 ± 0.6 to 5.0 ± 0.5, p = 0.74). The C-peptide/glucose ratio also increased significantly in the TZD group (from 1.9 ± 0.3 to 3.1 ± 0.3, p = 0.0003) whereas it remained unchanged in the CTRL group (from 3.4 ± 0.7 to 3.4 ± 0.3, p = 0.97). Furthermore, the C-peptide/glucose ratio of the TZD group, which was significantly lower at baseline compared with the CTRL group (1.9 ± 0.3 vs. 3.4 ± 0.7, p = 0.04), caught up to its level during treatment (3.1 ± 0.3 vs. 3.4 ± 0.3, p = 0.48). Conclusion: Thiazolidinediones seem to induce recovery of pancreatic beta cell function, independently of the correction of glucose toxicity.Keywords
This publication has 10 references indexed in Scilit:
- Troglitazone in Combination With Sulfonylurea Restores Glycemic Control in Patients With Type 2 DiabetesDiabetes Care, 1998
- Effect of Troglitazone on B Cell Function, Insulin Sensitivity, and Glycemic Control in Subjects with Type 2 Diabetes MellitusJournal of Clinical Endocrinology & Metabolism, 1998
- Metabolic Effects of Troglitazone Monotherapy in Type 2 Diabetes MellitusAnnals of Internal Medicine, 1998
- Leptin- or troglitazone-induced lipopenia protects islets from interleukin 1beta cytotoxicity.JCI Insight, 1997
- Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance.JCI Insight, 1997
- Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin or troglitazoneAmerican Journal of Physiology-Endocrinology and Metabolism, 1996
- Inhibitory effects of fatty acids on glucose-regulated b-cell function: Association with increased islet triglyceride stores and altered effect of fatty acid oxidation on glucose metabolismMetabolism, 1996
- Prevention of diabetes does not completely prevent insulin secretory defects in the ZDF ratAmerican Journal of Physiology-Endocrinology and Metabolism, 1995
- Effects of Troglitazone (CS-045) on insulin secretion in isolated rat pancreatic islets and HIT cells: an insulinotropic mechanism distinct from glibenclamideDiabetologia, 1995
- Characterization of CS-045, a new oral antidiabetic agent, II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome inMetabolism, 1991